HDAC9 and T-cell non-Hodgkin lymphoma: Increased acetylation of histone H3 upon treatment with 3ClQuin-SAHA was also seen in the four T-cell lymphoma cell lines (Figure 4d), confirming the HDAC-inhibitory activity of the compound also for the hematologic cancer cell models.